Brian Canter PhD

Brian Canter is an Assistant Policy Research Director on the Biomedical Innovation team working on policy solutions to improve development, regulatory review, and evidence generation for broadening access and availability to medical products. He manages one of the Biomedical Innovation team's cooperative agreements with the U.S. Food and Drug Administration (FDA).

Brian's portfolio of work spans several key areas within the biomedical innovation space. As the lead researcher on regulatory considerations to enable greater competition for biologics, he has evaluated the value of the interchangeability designation and derived strategies to foster future biosimilar development for cell and gene therapies. Supporting the Institute's thought leadership to modernize clinical trials, Brian guides the policy work for the Coalition for Advancing Clinical Trials at the Point of Care. Brian has also managed several projects within the  Institute's regulatory science work, including public meetings convened with FDA to advance clinical trial innovation and premarket safety analytics.

In addition to biomedical innovation, Brian has done extensive work within the Institute's 21st Century Public Health and Population Health portfolio. He oversaw a project focused on addressing the burden of respiratory viruses through reduction of disease transmission. During the COVID-19 pandemic, Brian led the Institute's work to maximize adoption of therapeutics, with a focus on Test-to-Treat pathways.

Prior to joining Duke-Margolis, Brian completed a PhD in Biomedical Sciences with a focus in Biomedical Engineering from Rutgers University. His thesis research focused on utilizing radiation therapy systemically to treat metastatic breast cancer that spread to bone. Brian also graduated with a Bachelor of Science in Biomedical Engineering from Tufts University.